Top Stories
An initial pilot will test the round-the-clock support tool in patients with desmoid tumours and NF1-related plexiform neurofibromas.
Boston-based AI Proteins will create novel therapeutic candidates from scratch against undisclosed targets.
The AI firm will integrate Orchestra's AI agents with its Rosalind AI model and tools for life sciences research.
The guidance clarifies when content should be considered FDA-required labelling rather than promotional labelling.
The collaboration will explore use cases that could improve clinical-trial efficiency, including identifying eligible patients earlier and easier, across several disease areas.
Conference News
SEATTLE--(BUSINESS WIRE)-- Compvide, Inc. today announced the commercial launch of its CIMED platform. The CIMED-AP, CIMED-LP, and CIMED-CP kits assess the alternative, lectin, and classical complemen...
Foundation Medicine to host series of expert-led booth talks to highlight how its driving innovation in precision diagnosticsBOSTON--(BUSINESS WIRE)-- Foundation Medicine, Inc., a global, patient-focu...
HEADSTART-ACS study conducted in collaboration with Indonesia’s National Cardiovascular Center in world’s fourth most populous country, representing strategically significant market of 288 million peo...
AI is demonstrating potential in an expanding variety of role within oncology care, from cancer-risk assessment, diagnostic review, multidisciplinary decisions, and patient communication.
Late-breaking oral presentation highlights the role of ultrasensitive ctDNA in drug development; first data from prospective B-STRONGER-1 study in early-stage triple-negative breast cancerFREMONT, Cal...
